Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose FOY-305 (camostat mesilate) in healthy Japanese adult males
jRCT2080225230Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camostat mesilate in coronavirus disease 2019 (COVID-19), sponsored by Ono Pharmaceutical. Primary endpoints: Safety and tolerability of FOY-305 600 mg four times daily and Pharmacokinetics of FOY-305 under different food conditions. Started Jun 2020; status: completed.
02
Drugs
camostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2080225230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225230.